ACTRN12607000208404尚未招募3 期
A randomised phase 3/4 study to compare the postoperative effects of morphine versus tramadol/ketamine/parecoxib analgesia on respiratory obstructions, apnoeas and oxygen desaturation.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •Obese (BMI>29) patients or airway abnormality on preoperative anaesthesia examination.Likely to require postoperative morphine or equivalent analgesia.Postoperative overnight hospital stay.
排除标准
- •Intrathoracic or upper-abdominal surgery. Previous adverse reaction to any study drugs including nausea or vomiting.
研究者
相似试验
已完成
不适用
A randomised prospective phase III comparison of paclitaxel - carboplatin versus docetaxel - carboplatin as first line chemotherapy in stage Ic-IV epithelial ovarian cancerOvaryCancerISRCTN31374767Cancer Research UK (CRUK) (UK)
进行中（未招募）
1 期
A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancernresectable non metastatic stage III non small cell lung carcinoma eligible for concomitant radiochemotherapyMedDRA version: 9.1Level: HLGTClassification code 10038666Term: Respiratory and mediastinal neoplasms malignant and unspecifiedEUCTR2006-004726-91-FRCHRU de Lille246
已完成
3 期
A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400 mg daily versus imatinib 800 mg daily versus imatinib plus PEG interferon-alpha 2a (Pegasys) in patients with newly-diagnosed chronic phasechronic myeloid leukaemiaChronic Myeloid LeukaemiaCancerISRCTN59346371ewcastle upon Tyne Hospitals Trust (UK)2,466
已完成
3 期
Study to find out if restricting raw fruits in patients with blood cancer can reduce infections.CTRI/2018/01/011418Cancer Institute200
已完成
3 期
Steroid tablets for preventing tiredness in cancer patients receiving chemotherapy medicine.CTRI/2018/08/015222Cancer Institute126